Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Corporate Update (September 2024)
9 slides from Bristol-myers Squibb's corporate update, Sep 26, 2024
Slide 1: U.S. FDA Approval of Cobenfy: Investor Overview
U.S. FDA Approval of Cobenfy September 26, 2024 Investor Overview Not for Product Promotional Use
Slide 2: Forward looking statements
Forward looking statements This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes
Slide 3: Now approved in the U.S. for the treatment of schizophrenia in adults
Now approved in the U.S. for the treatment of schizophrenia in adults First-in-class muscarinic agonist1 for the treatment of schizophrenia First new mechanism in decades for 1.6M treated schizophrenia patients in the U.S. • ~60-70% of patients not well managed with current treatments Compelling eff
Slide 4: Cobenfy delivered powerful efficacy at five weeks consistently across two phase 3 pivotal studies
Cobenfy delivered powerful efficacy at five weeks consistently across two phase 3 pivotal studies Change from baseline in PANSS total score at week 5 EMERGENT-21,a,b EMERGENT-32,3,a,b Interpreting Total PANSS Score4,5 (97.7, 98.2) (96.7, 97.3) Baseline Week 2 Week 3 Week 4 Week 5 Baseline Week 2 Wee
Slide 5: We are employing a comprehensive go-to-market strategy
We are employing Patients & care a comprehensive partners go-to-market strategy Patients and their Adults with Administrative Psychiatrists, care teams schizophrenia staff psychiatric APNs Psychiatrists, Key prescribers psychiatric APNs Community mental Care centers for health centers and schizophre
Slide 6: Building a strong proposition with payor engagement
Building a strong proposition with payor engagement1 Key dynamics Medicaid ~45% • Majority government payor model (~85%) Medicare • Anticipate majority of access 40% by 2H25 Commercial / Other ~15% 4Q24 1H25 2H25 1See “Forward-Looking Statements” Not for Product Promotional Use 6
Slide 7: Cobenfy sales ramp based on monthly paid script volumes
Sampling strategy among prescribers during patient Cobenfy sales initial titration ramp based on ~60K monthly NBRx1 in schizophrenia available from monthly paid patients going through a new treatment decision script volumes enabled by Analogs suggest ~50% of patients are still on drug at access expa
Slide 8: Cobenfy: First-in-class muscarinic agonist with potential to treat numerous complex psychiatric conditions
Cobenfy: First-in-class muscarinic agonist1 with potential to treat numerous complex psychiatric conditions impacting 100M+ people globally2 ONGOING PROGRAMS PLANNED PROGRAMS Adjunctive Alzheimer’s Alzheimer’s Alzheimer’s Bipolar I ASD Schizophrenia Schizophrenia Psychosis Agitation Cognition Disord
Slide 9: Bristol Myers Squibb
(Il Bristol Myers Squibb”
Bristol-Myers Squibb Company — Corporate Update (September 2024) on 6ix